Aromatase Inhibitors in Early Breast Cancer
Author Information
Author(s): PE L0nning
Primary Institution: Haukeland University Hospital, Bergen, Norway
Hypothesis
Can aromatase inhibitors like anastrozole provide benefits over tamoxifen in treating early breast cancer in post-menopausal women?
Conclusion
Anastrozole shows promise in improving outcomes for post-menopausal women with early breast cancer compared to traditional treatments.
Supporting Evidence
- Anastrozole increased median survival time from 22.5 months to 26.7 months compared to megestrol acetate.
- The 2-year survival rate improved from 46.3% to 56.1% with anastrozole.
- Anastrozole causes significantly less weight gain than megestrol acetate.
Takeaway
This study looks at a new medicine called anastrozole that might help women with early breast cancer feel better and live longer.
Methodology
Overview analysis of two prospective, randomized, phase III trials comparing anastrozole with megestrol acetate.
Limitations
The long-term effects of anastrozole on bone density and lipid profiles are still being studied.
Participant Demographics
Post-menopausal women with early breast cancer.
Statistical Information
P-Value
0.002
Statistical Significance
p=0.002
Want to read the original?
Access the complete publication on the publisher's website